Topics:

New Drug Application Filed for Vandetanib in Second-Line NSCLC

New Drug Application Filed for Vandetanib in Second-Line NSCLC

AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.

 
Loading comments...
Please Wait 20 seconds or click here to close